Equity Overview
Price & Market Data
Price: $0.73
Daily Change: +$0.0185 / 2.54%
Daily Range: $0.70 - $0.73
Market Cap: $8,354,564
Daily Volume: 50,017
Performance Metrics
1 Week: -6.41%
1 Month: -15.48%
3 Months: -21.71%
6 Months: -51.92%
1 Year: -56.43%
YTD: -16.30%
Company Details
Employees: 8
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.